Effects of Depot Medroxyprogesterone Acetate on Bone Density and Bone Metabolism before and after Peak Bone Mass: A Case-Control Study | Zendy

Jennifer Walsh | Zendy; Richard Eastell | Zendy; Nicola Peel | Zendy

Open Access

Effects of Depot Medroxyprogesterone Acetate on Bone Density and Bone Metabolism before and after Peak Bone Mass: A Case-Control Study

Author(s) -

Jennifer Walsh,

Richard Eastell,

Nicola Peel

Publication year - 2008

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2007-2201

Subject(s) - medroxyprogesterone acetate , bone remodeling , medicine , endocrinology , medroxyprogesterone , bone density , estrogen , dehydroepiandrosterone sulfate , bone mineral , hormone , confounding , osteoporosis , physiology , androgen

Depot medroxyprogesterone acetate (DMPA; Depo-Provera, Tadworth, UK) contraception is used by more than 9 million women worldwide and has a high usage among teenagers in the United Kingdom and the United States. Previous studies have found that DMPA use is associated with a bone density deficit.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research